Company intelligence / Profile preview

RDO Pharm

Foshan, Guangdong Province, Chinaadisinsight.springer.com ↗

Ownership: Private
Development stage: Other

Overview

RDO Pharm has completed a Phase 3 clinical trial (NCT04233476) for 99mTc-3PRGD2 SPECT/CT for integrin αVβ3 imaging of lung cancer and mapping lymph node metastases. The trial was a prospective multicenter, self-controlled study[1].

Therapeutic areas: Oncology
Modalities: Radiopharmaceuticals
Industry: Protein Biomarker Diagnostics

Partnerships

Peking University (originator organization)[1]

Beyond the preview

Go deeper on RDO Pharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RDO Pharm.

Explore the full profile